CD8A and renal cell carcinoma: While these promising results have prompted the initiation of a Phase 1/2 clinical trial in solid tumors, including RCC, challenges remain as NK infiltration into RCC tumors is reported to be limited compared with CD8 T cells (49) and yields a dysfunctional, poorly cytotoxic NK cell phenotype (50).